Diagonal Health

Publications

  1. Accelerating Innovation For Better Health: A MITRE Framework Supporting The Proposed Advanced Research Projects Agency For Health (ARPA-H). MITRE Corporation, Sep 15, 2021
  2. Covid-19 will not“magically disappear”: Why access to widespread testing is paramount. American Journal of Hematology, Dec. 2020. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26059  
  3. FDA Regulation of Laboratory-Developed Tests: What to Expect, How to Prepare. Arnold & Porter Advisory, 2016.
  4. Post-Election Analysis 2016: Healthcare, Life Sciences & FDA.  Arnold & Porter Advisory, 2016. 
  5. Medicare physician payment: Prepare to ‘MACRA-mize’ your practice.  www.healio.com, 2015.
  6. Final Meaningful Use Rules Add Short-Term Flexibility. Arnold & Porter Advisory, 2015.
  7. FDA Regulation Catches Up To Next-Gen Gene Sequencing. Health Law360 New York, 2015.
  8. House Energy and Commerce Committee Approves 21st Century Cures Legislation.  Arnold & Porter Advisory, 2015.
  9. Saying Farewell to the Sustainable Growth Rate: Are Physicians Better Off Now?  Arnold & Porter Advisory, 2015.
  10. Ferdinand KC, Orenstein D, Hong Y, Journigan JG, Trogdon J, Bowman J, et al. “Health Economics of Cardiovascular Disease:  Defining the Research Agenda.”  CVD Prevention and Control, 2011.
  11. Ali R, Bowman J, Carino T. Untangling the Potential Impact of Comparative Effectiveness Research on Pharmaceutical Innovation.  National Pharmaceutical Council, 2009.
  12. Bowman J, Rousseau A, Silk D, Harrison C. “Access to Cancer Drugs Under Medicare Part D:  Formulary Placement and Beneficiary Cost Sharing in 2006.”  Health Affairs, 2006.
  13. Blum J, Bowman J, White C. The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums. Kaiser Family Foundation 2005.
  14. Congressional Budget Office. A Detailed Description of CBO’s Cost Estimate for the Medicare Prescription Drug Benefit, Jul 2004.